139 related articles for article (PubMed ID: 38378035)
21. Dynamic Contrast-Enhanced Perfusion MRI and Diffusion-Weighted Imaging in Grading of Gliomas.
Arevalo-Perez J; Peck KK; Young RJ; Holodny AI; Karimi S; Lyo JK
J Neuroimaging; 2015; 25(5):792-8. PubMed ID: 25867683
[TBL] [Abstract][Full Text] [Related]
22. Effects of artery input function on dynamic contrast-enhanced MRI for determining grades of gliomas.
Jia L; Wu X; Wan Q; Wan L; Jia W; Zhang N
Br J Radiol; 2021 Mar; 94(1119):20200699. PubMed ID: 33332981
[TBL] [Abstract][Full Text] [Related]
23. Application of Distributed Parameter Model to Assessment of Glioma IDH Mutation Status by Dynamic Contrast-Enhanced Magnetic Resonance Imaging.
Li Z; Zhao W; He B; Koh TS; Li Y; Zeng Y; Zhang Z; Zhang J; Hou Z
Contrast Media Mol Imaging; 2020; 2020():8843084. PubMed ID: 33299387
[TBL] [Abstract][Full Text] [Related]
24. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma.
Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F
World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307
[TBL] [Abstract][Full Text] [Related]
25. Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status.
Delfanti RL; Piccioni DE; Handwerker J; Bahrami N; Krishnan A; Karunamuni R; Hattangadi-Gluth JA; Seibert TM; Srikant A; Jones KA; Snyder VS; Dale AM; White NS; McDonald CR; Farid N
J Neurooncol; 2017 Dec; 135(3):601-609. PubMed ID: 28871469
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic Values of DCE-MRI and DSC-MRI for Differentiation Between High-grade and Low-grade Gliomas: A Comprehensive Meta-analysis.
Liang J; Liu D; Gao P; Zhang D; Chen H; Shi C; Luo L
Acad Radiol; 2018 Mar; 25(3):338-348. PubMed ID: 29223713
[TBL] [Abstract][Full Text] [Related]
27. Comparison of Genetic Profiles and Prognosis of High-Grade Gliomas Using Quantitative and Qualitative MRI Features: A Focus on G3 Gliomas.
Hong EK; Choi SH; Shin DJ; Jo SW; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SH; Won JK; Kim TM; Park CK; Kim IH; Lee ST
Korean J Radiol; 2021 Feb; 22(2):233-242. PubMed ID: 32932560
[TBL] [Abstract][Full Text] [Related]
28. Intergrating conventional MRI, texture analysis of dynamic contrast-enhanced MRI, and susceptibility weighted imaging for glioma grading.
Su CQ; Lu SS; Han QY; Zhou MD; Hong XN
Acta Radiol; 2019 Jun; 60(6):777-787. PubMed ID: 30244590
[TBL] [Abstract][Full Text] [Related]
29. Molecular genetics of adult grade II gliomas: towards a comprehensive tumor classification system.
Figarella-Branger D; Bouvier C; de Paula AM; Mokhtari K; Colin C; Loundou A; Chinot O; Metellus P
J Neurooncol; 2012 Nov; 110(2):205-13. PubMed ID: 22890969
[TBL] [Abstract][Full Text] [Related]
30. Combined texture analysis of dynamic contrast-enhanced MRI with histogram analysis of diffusion kurtosis imaging for predicting IDH mutational status in gliomas.
Pan T; Su CQ; Tang WT; Lin J; Lu SS; Hong XN
Acta Radiol; 2023 Sep; 64(9):2552-2560. PubMed ID: 37331987
[TBL] [Abstract][Full Text] [Related]
31. Glioma grading by microvascular permeability parameters derived from dynamic contrast-enhanced MRI and intratumoral susceptibility signal on susceptibility weighted imaging.
Li X; Zhu Y; Kang H; Zhang Y; Liang H; Wang S; Zhang W
Cancer Imaging; 2015 Mar; 15(1):4. PubMed ID: 25889239
[TBL] [Abstract][Full Text] [Related]
32. DSC and DCE Histogram Analyses of Glioma Biomarkers, Including IDH, MGMT, and TERT, on Differentiation and Survival.
Zhang HW; Lyu GW; He WJ; Lei Y; Lin F; Wang MZ; Zhang H; Liang LH; Feng YN; Yang JH
Acad Radiol; 2020 Dec; 27(12):e263-e271. PubMed ID: 31983532
[TBL] [Abstract][Full Text] [Related]
33. Diffusion kurtosis imaging in evaluating gliomas: different region of interest selection methods on time efficiency, measurement repeatability, and diagnostic ability.
Chu JP; Song YK; Tian YS; Qiu HS; Huang XH; Wang YL; Huang YQ; Zhao J
Eur Radiol; 2021 Feb; 31(2):729-739. PubMed ID: 32857204
[TBL] [Abstract][Full Text] [Related]
34. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.
Leu K; Ott GA; Lai A; Nghiemphu PL; Pope WB; Yong WH; Liau LM; Cloughesy TF; Ellingson BM
J Neurooncol; 2017 Aug; 134(1):177-188. PubMed ID: 28547590
[TBL] [Abstract][Full Text] [Related]
35. Conventional MR-based Preoperative Nomograms for Prediction of IDH/1p19q Subtype in Low-Grade Glioma.
Liu Z; Zhang T; Jiang H; Xu W; Zhang J
Acad Radiol; 2019 Aug; 26(8):1062-1070. PubMed ID: 30393056
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Value of Preoperative MRI Metrics for Diffuse Lower-Grade Glioma Molecular Subtypes.
Darvishi P; Batchala PP; Patrie JT; Poisson LM; Lopes MB; Jain R; Fadul CE; Schiff D; Patel SH
AJNR Am J Neuroradiol; 2020 May; 41(5):815-821. PubMed ID: 32327434
[TBL] [Abstract][Full Text] [Related]
37. Measurements of diagnostic examination performance using quantitative apparent diffusion coefficient and proton MR spectroscopic imaging in the preoperative evaluation of tumor grade in cerebral gliomas.
Server A; Kulle B; Gadmar ØB; Josefsen R; Kumar T; Nakstad PH
Eur J Radiol; 2011 Nov; 80(2):462-70. PubMed ID: 20708868
[TBL] [Abstract][Full Text] [Related]
38. Simplified perfusion fraction from diffusion-weighted imaging in preoperative prediction of IDH1 mutation in WHO grade II-III gliomas: comparison with dynamic contrast-enhanced and intravoxel incoherent motion MRI.
Wang X; Cao M; Chen H; Ge J; Suo S; Zhou Y
Radiol Oncol; 2020 Jun; 54(3):301-310. PubMed ID: 32559177
[TBL] [Abstract][Full Text] [Related]
39. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS
Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414
[TBL] [Abstract][Full Text] [Related]
40. Conventional Magnetic Resonance Features for Predicting 1p19q Codeletion Status of World Health Organization Grade II and III Diffuse Gliomas.
Peng X; Yishuang C; Kaizhou Z; Xiao L; Ma C
J Comput Assist Tomogr; 2019; 43(2):269-276. PubMed ID: 30371623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
